Relistor, produced by Tarrytown, N.Y.-based Progenics Pharmaceuticals, was originally approved in 2008 as an injectable.
Protogenics sold the licensing rights of Relistor to Raleigh, N.C.-based Salix Pharmaceuticals in 2011, which was later acquired by Canada-based Valeant for $11.1 billion in 2015.
Valeant agreed to give Progenics a $50 million milestone payment pending the FDA approval.
Valeant and Progenics hope to launch Relistor in the third quarter of 2016.
More articles on the drug market:
India’s growing role in the US generic drug market: 5 things to know
Patients expect discounts for soaring drug costs: 3 things to know
Brexit’s threat to the drug industry doesn’t scare Novartis
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
